Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The MAX Study: A Randomised Phase II/III Study to Evaluate the Role of Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer

NCT00294359 is registered in ClinicalTrials.gov with Australasian Gastro-Intestinal Trials Group as lead sponsor.

NCT NCT00294359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00294359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The MAX Study: A Randomised Phase II/III Study to Evaluate the Role of Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer
Lead sponsor
Australasian Gastro-Intestinal Trials Group
Phase
Phase 2/3
Overall status
Completed
Start date
June 30, 2005
Completion date
July 31, 2007
Enrollment
333 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer